Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week randomized double-blind placebo-controlled trial of dapagliflozin plus metformin in type 2 diabetes mellitus
2010-019511-37Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in HbA1c at 16 weeks. Started Aug 2010; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019511-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019511-37.